Todd Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics, Inc., filed a Form 4 on November 17, 2026, disclosing a gift of 144,232 shares of common stock on November 13, 2026, to an irrevocable trust.

Key Highlights

  • Reporting person: Todd Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
  • Transaction: 144,232 shares of common stock disposed of via gift (transaction code G) on November 13, 2026, at a price of $0
  • Recipient: The TFW-NH 2026 Trust, an irrevocable trust for which IQ-EQ Trust Company, U.S., LLC serves as trustee
  • Post-transaction ownership: Watanabe directly holds 568,594 shares of common stock following the transaction
  • Trust exclusion: The filing states the securities held by the trust are not reported as beneficially owned by Watanabe, as he is not a trustee, does not have investment control, and cannot revoke the trust

Watanabe Transfers Shares to Irrevocable Trust, Retaining Direct Stake of 568,594 Shares

According to the Form 4 filed with the SEC on November 17, 2026, Todd Watanabe, who serves as President and Chief Executive Officer of Arcutis Biotherapeutics, Inc., disposed of 144,232 shares of the company's common stock on November 13, 2026. The filing identifies the transaction code as G, indicating a gift, with a reported price of $0.

The filing discloses that the shares were gifted to the TFW-NH 2026 Trust, described as an irrevocable trust with IQ-EQ Trust Company, U.S., LLC serving as trustee. The filing states that "the Reporting Person is not a trustee of the trust, does not have investment control over the trust securities, and does not have power to revoke the trust," and that accordingly the securities held by the trust are not reported as beneficially owned by Watanabe.

Following the reported transaction, the filing shows Watanabe directly holds 568,594 shares of Arcutis common stock. No derivative securities transactions were reported in Table II of the form. The Form 4 was signed by Latha Vairavan as Attorney-in-Fact for Todd Watanabe and filed on November 17, 2026.

What Was Disclosed

Arcutis Biotherapeutics CEO Todd Watanabe disclosed a gift of 144,232 common shares to the TFW-NH 2026 Trust on November 13, 2026. Following the transfer, Watanabe's direct beneficial ownership stands at 568,594 shares, per the filing.